Paolo Tarantino: Testing T-DXd vs chemo for endocrine-refractory HR+ MBC

Paolo Tarantino shared a post on X:

“Previously presented at ASCO24 by Giuseppe Curigliano, the impressive results of DB06, testing T-DXd vs chemo for endocrine-refractory HR+ MBC, are now published in The New England Journal of Medicine.

Take home points:

1. Even HR+/HER2-0 (ultralow) tumors derive huge benefit from T-DXd. From now on, all HER2-0 tumor should be further qualified as “ultralow” or “null” in pathology reports
2. Can consider using T-DXd as first cytotoxic line, particularly in patients with aggressive course of disease that may lose the opportunity of getting T-DXd in later lines
3. Careful monitoring for ILD remains critical to prevent severe cases.”

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

Authors: Aditya Bardia, et al.

Source: Paolo Tarantino/X

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.